TD Cowen analyst Dan Brennan raised the firm’s price target on Exact Sciences (EXAS) to $86 from $82 and keeps a Buy rating on the shares. The firm said the final Medicare price for Cologuard Plus is better than expected leading the firm to raise its estimates.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Closing Bell Movers: Semtech rises, Zoom falls after earnings
- Exact Sciences to present 10 abstracts on Precision Oncology portfolio at SABCS
- Exact Sciences to present abstracts on multi-cancer early detection test
- Exact Sciences price target lowered to $75 from $85 at Piper Sandler
- Exact Sciences price target lowered to $70 from $75 at Wells Fargo